MNG1091
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.492
- ALLOGRAFT_REJECTION+0.388
- INTERFERON_ALPHA_RESPONSE+0.386
- OXIDATIVE_PHOSPHORYLATION+0.382
- INTERFERON_GAMMA_RESPONSE+0.372
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.357
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.347
- MYC_TARGETS_V2+0.341
- DNA_REPAIR+0.269
- COAGULATION+0.242
Top 10 suppressed
- PROTEIN_SECRETION-0.338
- ANDROGEN_RESPONSE-0.280
- UV_RESPONSE_DN-0.243
- HEME_METABOLISM-0.215
- CHOLESTEROL_HOMEOSTASIS-0.198
- ESTROGEN_RESPONSE_EARLY-0.187
- HEDGEHOG_SIGNALING-0.186
- SPERMATOGENESIS-0.174
- PANCREAS_BETA_CELLS-0.164
- BILE_ACID_METABOLISM-0.116
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-O2-A52Q-01A-11R-A26W-07 | — | cohortA1 | 0.786 |
| 2 | 77907EB2-E529-4633-A580-C6DD7993A704 | — | — | 0.777 |
| 3 | 21f65654-07a2-4b27-b511-2497fa298d0e | — | — | 0.771 |
| 4 | SRR8518316 | — | D | 0.770 |
| 5 | MDT-AP-0825 | Med | Medulloblastoma | 0.763 |
| 6 | MNG1097 | — | — | 0.762 |
| 7 | TCGA-GU-A762-01A-11R-A33J-07 | — | — | 0.762 |
| 8 | E00A399D-E6C3-439D-8E70-A7AD5DF5F5E2 | — | — | 0.761 |
| 9 | TCGA-GU-A766-01A-11R-A32O-07 | — | — | 0.753 |
| 10 | DRR168610 | — | — | 0.751 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.492 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.388 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.386 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.382 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.372 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.357 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.347 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.341 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.269 | Idelalisib | — uncovered |
| COAGULATION | 0.242 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.235 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.207 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.194 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.179 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.176 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.169 | Inavolisib | — uncovered |
| MYOGENESIS | 0.148 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.135 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.126 | Inavolisib | — uncovered |